{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:25:53Z","timestamp":1784690753007,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) sequencing complements tissue-based next-generation sequencing (NGS), offering noninvasive and serial testing. We explore the mutational landscape of renal cell carcinoma (RCC) using matched tissue and ctDNA data to assess complementarity and clinical significance of molecular alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the Tempus multimodal database, we retrospectively analyzed de-identified data from patients with RCC with concurrent tissue (Tempus xT) and ctDNA testing (Tempus xF). Patients with xT and xF matched samples (collected \u00b190\u2009days of one another) were included. We evaluated socio-demographic and clinical characteristics and selected pathogenic somatic short variants (PSSVs) and copy number variants (CNV). Analyses were restricted to the 104 genes shared by all assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 392 patients, 66% (n\u2009=\u2009259) had metastatic disease. The median time from tissue to blood collection was 21\u2009days. The most common tissue sites were kidney (49%, n\u2009=\u2009189) and bone (11%, n\u2009=\u200943). Frequently altered tissue-tested genes were: VHL (59%), PBRM1 (32%), and SETD2 (23%). Most frequently altered genes in ctDNA were TP53 (23%), VHL (18%), BAP1 (6%), and PBRM1 (5%); notably, 176 patients did not have any pathogenic or likely pathogenic variants detected in the 104 genes analyzed. Complementary ctDNA and tissue testing detected 6% more alterations than tissue testing alone, with greater concordance in metastatic cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ctDNA testing offers complementary insights to tissue NGS in RCC, particularly in metastatic disease, suggesting the potential utility of ctDNA in advanced RCC. Longitudinal analysis may enhance delineation of biomarkers of response and resistance at mutation and ctDNA fraction levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag123","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:52:49Z","timestamp":1775044369000},"source":"Crossref","is-referenced-by-count":1,"title":["Concurrent tissue and circulating tumor DNA analysis in renal cell\u00a0carcinoma: insights from a multimodal database"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-5568","authenticated-orcid":false,"given":"Chinmay T","family":"Jani","sequence":"first","affiliation":[{"name":"University of Miami\/Sylvester Comprehensive Cancer Center , Miami, FL, 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tran","sequence":"additional","affiliation":[{"name":"University of California San Diego , La Jolla, CA, 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Jaeger","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc ., Chicago, IL, 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjie","family":"Dong","sequence":"additional","affiliation":[{"name":"Scripps Institute , San Diego, La Jolla, CA, 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Husni","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc ., Chicago, IL, 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C","family":"Stoppler","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc ., Chicago, IL, 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Hockenberry","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc ., Chicago, IL, 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mercer","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc ., Chicago, IL, 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[{"name":"City of Hope , Duarte, CA, 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Center , Salt Lake City, UT, 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA, 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Rose","sequence":"additional","affiliation":[{"name":"University of California San Diego , La Jolla, CA, 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[{"name":"University of California San Diego , La Jolla, CA, 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R","family":"McKay","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA, 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2026042912064178200_oyag123-B1","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/0008-5472.CAN-17-0885","article-title":"Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing","volume":"77","author":"Schwaederle","year":"2017","journal-title":"Cancer Res"},{"key":"2026042912064178200_oyag123-B2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.37349\/etat.2022.00104","article-title":"Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment","volume":"3","author":"Sato","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"key":"2026042912064178200_oyag123-B3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.euo.2021.04.005","article-title":"Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature","volume":"4","author":"Green","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026042912064178200_oyag123-B4","doi-asserted-by":"crossref","first-page":"103109","DOI":"10.1016\/j.critrevonc.2020.103109","article-title":"ctDNA as a cancer biomarker: a broad overview","volume":"155","author":"Pessoa","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026042912064178200_oyag123-B5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3892\/or.2023.8543","article-title":"Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease (review)","volume":"49","author":"Chen","year":"2023","journal-title":"Oncol Rep"},{"key":"2026042912064178200_oyag123-B6","doi-asserted-by":"crossref","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","article-title":"Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"2026042912064178200_oyag123-B7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1055-9965.EPI-14-0895","article-title":"Circulating tumor DNA is effective for the detection of EGFR mutation in non\u2013small cell lung cancer: a meta-analysis","volume":"24","author":"Qiu","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026042912064178200_oyag123-B8","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jtho.2023.05.027","article-title":"Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stages I to IIIA EGFR-Mutant non\u2013small cell lung cancer","volume":"18","author":"Jung","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026042912064178200_oyag123-B9","doi-asserted-by":"crossref","first-page":"103065","DOI":"10.1016\/j.critrevonc.2020.103065","article-title":"Circulating tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor\u2013a systematic review and meta-analysis","volume":"154","author":"Perdyan","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026042912064178200_oyag123-B10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eururo.2017.03.046","article-title":"Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma","volume":"72","author":"Pal","year":"2017","journal-title":"Eur Urol"},{"key":"2026042912064178200_oyag123-B11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13073-022-01146-3","article-title":"Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape","volume":"14","author":"Golkaram","year":"2022","journal-title":"Genome Med"},{"key":"2026042912064178200_oyag123-B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14737159.2019.1665510","article-title":"Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies","volume":"20","author":"Cimadamore","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"2026042912064178200_oyag123-B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euros.2021.12.006","article-title":"Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature","volume":"37","author":"Geertsen","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"2026042912064178200_oyag123-B14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ctrv.2013.10.003","article-title":"Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities","volume":"40","author":"Esposito","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"2026042912064178200_oyag123-B15","doi-asserted-by":"crossref","first-page":"e81468","DOI":"10.1371\/journal.pone.0081468","article-title":"Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. Khanin R, ed","volume":"8","author":"Kukita","year":"2013","journal-title":"PLoS One"},{"key":"2026042912064178200_oyag123-B16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1196\/annals.1448.025","article-title":"Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer","volume":"1137","author":"Schwarzenbach","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"2026042912064178200_oyag123-B17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clgc.2019.12.018","article-title":"Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma","volume":"18","author":"Bacon","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"2026042912064178200_oyag123-B18","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-21-0572","article-title":"Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma","volume":"27","author":"Zengin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026042912064178200_oyag123-B19","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"2026042912064178200_oyag123-B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","article-title":"Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA","volume":"5","author":"Finkle","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026042912064178200_oyag123-B21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/24684570241303346","article-title":"Liquid biopsy for renal cell carcinoma: a comprehensive review of techniques, applications, and future prospects","volume":"8","author":"Jani","year":"2024","journal-title":"Kidney Cancer (Clifton, Va.)"},{"key":"2026042912064178200_oyag123-B22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-018-0530-4","article-title":"The role of circulating tumor DNA in renal cell carcinoma","volume":"19","author":"Bergerot","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"2026042912064178200_oyag123-B23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2026042912064178200_oyag123-B24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"2026042912064178200_oyag123-B25","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026042912064178200_oyag123-B26","doi-asserted-by":"crossref","first-page":"681441","DOI":"10.3389\/fonc.2021.681441","article-title":"The emerging role of poly (ADP-Ribose) polymerase inhibitors as effective therapeutic agents in renal cell carcinoma","volume":"11","author":"Pletcher","year":"2021","journal-title":"Front Oncol"},{"key":"2026042912064178200_oyag123-B27","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.1016\/j.clgc.2019.06.013","article-title":"Immunogenomics of metastatic clear-cell renal cell carcinoma: remarkable response to nivolumab in a patient with a pathogenic germ line BRCA1 mutation","volume":"17","author":"Beulque","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2026042912064178200_oyag123-B28","doi-asserted-by":"crossref","first-page":"e2400406","DOI":"10.1200\/PO-24-00406","article-title":"Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway-deficient neoplasms","volume":"8","author":"George","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026042912064178200_oyag123-B29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/oncolo\/oyad216.002","article-title":"ORCHID: a phase II study of olaparib in metastatic renal cell carcinoma patients harborIng a BAP1 or other DNA repair gene mutations","volume":"28","author":"Ged","year":"2023","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag123\/67726926\/oyag123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag123\/67726926\/oyag123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag123\/67726926\/oyag123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:06:50Z","timestamp":1777478810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag123\/8572653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag123","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,3]]},"article-number":"oyag123"}}